CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 345 enrolled
Drug / intervention
lurbinectedin (PM01183)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02454972
NCT02454972Phase 2Completed
CompareCT.gov

A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors

PharmaMar·interventional·Posted May 27, 2015·Updated Mar 2, 2023

In Brief

A Phase 2 clinical trial evaluating lurbinectedin (PM01183) for Advanced Solid Tumors. Completed, enrolled 345 participants across 40 sites in 9 countries.

Detailed Summary

Multicenter, open-label, exploratory, phase II clinical trial to evaluate the efficacy and safety of PM01183 in previously treated patients with advanced solid tumors

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors
CountriesBelgium, France, Germany, Italy, Spain, Sweden, Switzerland, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 27, 2015
Enrollment StartAug 25, 2015
Primary CompletionSep 18, 2020
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 11.1 years ago

Interventions

lurbinectedin (PM01183)drug